September 1997 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
Anti-IL-1 treatments might help with certain types of hair loss in people with high inflammation.
September 1997 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
Blocking IL-1 could help treat some hair loss conditions; alopecia affects liver detox systems; spironolactone is better than finasteride for female hair growth; focusing on the catagen hair phase could lead to new alopecia treatments.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
Dutasteride at 0.5 mg/day does not significantly alter allopregnanolone levels, but higher doses (2.5 mg/day) do. Dutasteride may also have anti-neuroinflammatory effects, but the impact on neurosteroids is still debated.
The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
The user has been using finasteride and minoxidil for hair loss but experienced worsening temple recession. They suspect they might be more sensitive to testosterone and are considering trying RU58841 or CB 03 01 as additional treatments.